QCI Interpret for Oncology

Gaining insights with transcriptomic profiling and mechanistic modeling

June 11, 2021
In this webinar, Moritz Schütte, head of next-generation sequencing data analysis at Alacris, will explore the advantages of RNA sequencing alone or in combination with whole-exome sequencing as part of a precision oncology workflow.

In addition to discussing how RNA-seq identifies molecular alterations and illuminates the tumor microenvironment, Dr. Schütte will explain how mathematical modeling of molecular data can predict drug sensitivity. Applications will be shown for metastatic melanoma and acute lymphoblastic leukemia.

In this webinar, you will learn:

How comprehensive analysis is able to detect actionable targets not accessible by panel analysis;
How deep transcriptome profiling gives insights into the tumor microenvironment and immune composition;
How transcriptome sequencing can be applied for molecular profiling of acute lymphoblastic leukemias in relapse;
How mechanistic modeling offers a highly complementary information layer and enables in silico testing of drug response.

Related videos

QCI Interpret for Oncology

QCI Interpret One: Oncology variant interpretation just got more precise

1,025 views June 12, 2020

Competing to offer a comprehensive genomic profiling service for solid or...

QCI Interpret for Oncology

Precision medicine for any cancer assay on any platform

1,017 views May 29, 2019

For NGS cancer testing, keeping pace with new discoveries is a serious...

QCI Interpret for Oncology

Managing multiple biomarker therapeutic development

405 views September 12, 2019

For the past two decades, the paradigm in the field has been “one biomarker,...

QCI Interpret for Oncology

FASTQ to final report: Ultra-fast workflow for CGP

371 views July 21, 2022

As our molecular knowledge of cancer continually evolves, a new era in cancer...